Laurus Labs Limited has informed the Exchange about Credit Rating
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CARE Ratings has reaffirmed Laurus Labs' long-term bank facilities rating at CARE AA and short-term bank facilities at CARE A1+. Importantly, the outlook on the long-term rating was revised from Negative to Stable, signalling reduced credit risk. The agency cited improved performance in FY25, including growth in total operating income, higher profitability margins, and stronger debt coverage indicators. Both ratings remain at investment-grade levels, indicating strong financial health.
Positive for shareholders — the outlook upgrade reflects improving business fundamentals and reduced credit risk, which can lower borrowing costs and boost investor confidence. Short-term trading sentiment may improve, though the actual rating letter was reaffirmed rather than upgraded.